Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel Sites

MALARIA Clinical Trial

Official title:

Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel Sites

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05070520
• Other study ID #: 033/2020/CNERS
• Status: Completed
• Phase: Phase 4
• Start date: September 1, 2020
• Est. completion date: October 28, 2020

Study information

• Verified date: October 2021
• Source: Programme National de Lutte contre le Paludisme, Niger
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Niger, malaria is a major public health problem. It is the main cause of morbidity and mortality among children. The management of malaria cases is based on the principle of early diagnosis and rapid treatment with effective drugs. It is confronted with the appearance of strains resistant to antimalarial drugs, hence the need to monitor antimalarial drug sensitivity.

The study was conducted in three regions representing epidemiological strata of the country:

Agadez (Centre de santé Intégré of Dagamanet in the Health district of Agadez), Maradi (Centre de santé intégré of Guindaoua in Tessaoua) and Dosso (Centre de santé Intégré centre in Gaya). The protocol used is the WHO standardized protocol of 2009. Artemether/Lumefantrine (AL) was administered with a 28-day follow-up in children aged 3 months to 15 years. A Polymerase Chain Reaction (PCR) correction is planned to differentiate between treatment failure and re-infestation as well as a study of genes responsible for resistance on the main drugs used.

Description:

The study took place from September 1 to October 31, 2020 at the time of peak malaria transmission. It took place at three sentinel sites of the National Malaria Control Program (NMCP). These were in the regions of i) Agadez at the Centre de Santé Intégré (CSI) of Dagamanet in the Agadez district, ii) Dosso at the CSI centre in the health district (HD) of Gaya iii) Maradi at the CSI Guindaoua in the HD of Tessaoua. These sites were identified by the NMCP because of their high attendance rate and belong to 3 different malaria epidemiological strata.

As the treatment failure rate of artemether lumefantrine (AL) in the regions is unknown, 5% was chosen. With a confidence level of 95% and a precision around the estimate of 5%, a minimum of 73 patients were included. The number of patients was increased by 20% to account for possible dropouts and withdrawals during the 28/42 day follow-up period, 88 patients were included in the study per site.

The study drug is oral AL. It is one of the four antimalarial drugs selected by the Niger's NMCP for the management of malaria. The product consists of blister packs of 6 tablets, box of 30 of lot number K U142 with an expiration date of January 2022 and blister packs of 12 tablets, box of 30 of lot number K U456 with an expiration date of January 2022.

The AL combination was administered at a dose of 4 mg artemether and 24 mg lumefantrine per kg for three days. The AL was provided by the NMCP.

The different prescriptions were as follows:

• 5 to 15 Kg: 1 tablet, twice a day for three days.

• 15 to 25 Kg: 2 tablets, twice a day for three days.

• 25 to 35 kg: 3 tablets, twice a day for three days.

• Over 35 kg: 4 tablets, twice a day for three days.

The first day's intake was done under direct observation and possible side effects were noted. Any patient who persistently vomited after taking the medication was excluded from the study and treated with artesunate. Patients were followed up regularly until Day 28 and received a clinical examination with thick drop control and axillary temperature taking at Day 0, Day 1, Day 2, Day 3, Day 7, Day 14, Day 21, and Day 28. Capillary blood on filtered paper (Wattman) was routinely collected from all patients on the day of inclusion ( Day 0) and during follow-up for molecular analysis. For follow-up, the density of asexual parasite forms was assessed on the basis of 8 000 leukocytes per microliter of blood. All slides were read by two microscopists to ensure control. At the end of the follow-up, the response to treatment was classified according to clinical and parasitological criteria

Recruitment information / eligibility

• Status: Completed
• Enrollment: 259
• Est. completion date: October 28, 2020
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Months to 15 Years

Eligibility

Inclusion Criteria:

• Brachial circumference (BC) > 125 mm and P/T z-score > -2 Standard Deviation (SD)

• Age between three months and fifteen years,

• Monospecific Plasmodium falciparum infestation detected by microscopy;

• Parasitemia between 1000 and 200000 asexual parasitic forms/µl ;

• Axillary temperature =37.5° or history of fever in the past 24 hours ;

• Ability to take oral medications;

• Ability and willingness to adhere to the protocol for the duration of the study and to adhere to the visit schedule ;

• Informed consent of the accompanying person (guardian or parent).

Exclusion Criteria:

• Inability to take oral medications

• History of antimalarial treatment in the past two weeks, including sulfadoxine-pyrimethamine (SPAQ) for seasonal malaria chemoprevention (SMC)

• Lack of consent for pregnancy testing

• Presence of general danger signs in children under five years of age or signs of severe P. falciparum malaria as defined by World Health Organization (WHO);

• Mixed infestation or monospecific infestation with another Plasmodium species, detected by microscopic examination;

• Severe malnutrition defined by a BC <125 mm AND P/T z-score < -3 Standard Deviation (SD)

• Moderate malnutrition defined by a BC <125 mm AND a -3 =P/T z-score < -2 SD

• Febrile condition due to illnesses other than malaria (e.g., measles, acute lower respiratory tract infection, severe diarrheal illness with dehydration) or other known chronic or severe underlying illnesses (e.g., cardiac, renal, or liver disease, HIV/AIDS) ;

• Regular use of medications that may interfere with antimalarial pharmacokinetics;

• History of hypersensitivity or contraindication to any of the drugs tested or used as replacement therapy;

• Lack of informed consent from the patient or accompanying person

Related Conditions & MeSH terms

• MALARIA
• Malaria, Falciparum

Intervention

Drug:
• Artemether-lumefantrine
Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020

Locations

Country	Name	City	State
Niger	Programme National de Lutte Contre Le Paludisme	Niamey

Sponsors (1)

Lead Sponsor	Collaborator
Programme National de Lutte contre le Paludisme, Niger

Country where clinical trial is conducted

Niger, 

References & Publications (1)

Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000 Apr;94 Suppl 1:S1-90. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with asexual falciparum parasitaemia on Day 0.	Parasitaemia always refers to falciparum species. Mixed infections detected by light microscopy was excluded.	4 weeks
Primary	Number of patiants with presence of gametocytes on Day 0		4 weeks
Primary	Percentage of patients with danger signs of malaria on Day 1	Depending on the classification, a patient will be considered as having experienced treatment failure if the danger signs are associated with the presence of parasites.	4 weeks
Primary	Proportion of patients with 'adequate clinical and parasitological response' (ACPR) before PCR-corrected	absence of parasitaemia on day 28 (day 42), irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure	8 weeks
Primary	Proportion of patients with 'adequate clinical and parasitological response' (ACPR) after PCR-corrected	PCR analysis	24 weeks
Primary	Proportion of patients with 'early treatment failure' (ETF) before PCR-corrected	Danger signs or severe malaria on day 1, 2 or 3, in the presence of parasitaemia; Parasitaemia on day 2 higher than on day 0, irrespective of axillary temperature; Parasitaemia on day 3 with axillary temperature = 37.5 °C; and; Parasitaemia on day 3 = 25% of count on day 0	8 weeks
Primary	Proportion of patients with 'early treatment failure' (ETF) after PCR-corrected	-PCR analysis	24 weeks
Primary	Proportion of patients with 'late clinical failure' (LCF) before PCR-corrected	danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 28 (day 42) in patients who did not previously meet any of the criteria of early treatment failure; and; presence of parasitaemia on any day between day 4 and day 28 (day 42) with axillary temperature = 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure	8 weeks
Primary	Proportion of patients with 'late clinical failure' (LCF) after PCR-corrected	PCR analysis	24 weeks
Primary	Proportion of patients with 'late parasitological failure' (LPF) before PCR-corrected	presence of parasitaemia on any day between day 7 and day 28 (day 42) with axillary temperature < 37.5 °C in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure.	8 weeks
Primary	Proportion of patients with 'late parasitological failure' (LPF) after PCR-corrected	PCR analysis	24 weeks
Primary	Percentage of the known mutations associated with artemisinin resistance observed.	PCR analysis	24 weeks